Health & Biotech
Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level.
We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.
Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Check up: COVID-19 still sells but investors are looking for the next endorphin hit
Health & Biotech
Health: Bionomics looks to get ‘back on track’ as it switches into the fast lane for US approval
Health & Biotech
Health: Immutep bounces off decade-long lows thanks to cash from GSK
Health & Biotech
Fliers, flameouts and fakers: what happened in biotechland in 2018
Health & Biotech
Optiscan says it’s business-as-usual despite unrest among rebel shareholders
Health & Biotech
Battle for Optiscan heats up with second bid to overturn the board
Health & Biotech